Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
Phase 3 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)
Sponsor: Atox Bio Ltd
Terminated
Very slow enrollment of target patient population
Other Acute Kidney Injury trials with similar outcome
Listed as NCT03403751, this PHASE3 trial focuses on Acute Kidney Injury and Necrotizing Soft Tissue Infection and remains terminated or withdrawn. Sponsored by Atox Bio Ltd, it has been updated 16 times since 2018, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Terminated PHASE3
▶ Show 11 earlier versions
-
Feb 2021 — Oct 2021 [monthly]
Terminated PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Terminated PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2019 — Jul 2020 [monthly]
Recruiting PHASE3
Phase: PHASE2 → PHASE3
-
Jun 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Atox Bio Ltd
For direct contact, visit the study record on ClinicalTrials.gov .